ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,842.91
      0.11%
      US Tech 100
      20,203.20
      0.00%
      Dow Jones
      42,518.28
      0.52%
      Brent Oil
      79.735
      0.04%
      Bitcoin
      97,462.67
      0.99%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Monte Rosa Therapeutics Inc (GLUE) Quote

      Monte Rosa Therapeutics Inc

      Monte Rosa Therapeutics Inc (GLUE)

      NASDAQ
      5.56
      0.00
      (0.00%)
      Closed January 15 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      5.56
      Bid
      5.29
      Ask
      5.95
      Volume
      -
      0.00 Day's Range 0.00
      3.32 52 Week Range 12.40
      Market Cap
      341.588M
      Previous Close
      5.56
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      3,043,153
      Shares Outstanding
      61,436,740
      Dividend Yield
      -
      PE Ratio
      -2.52
      Earnings Per Share (EPS)
      -2.2
      Revenue
      -
      Net Profit
      -135.35M

      About Monte Rosa Therapeutics Inc

      Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enable... Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.monterosatx.com.
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Monte Rosa Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GLUE. The last closing price for Monte Rosa Therapeutics was $5.56. Over the last year, Monte Rosa Therapeutics shares have traded in a share price range of $ 3.32 to $ 12.40.

      Monte Rosa Therapeutics currently has 61,436,740 shares outstanding. The market capitalization of Monte Rosa Therapeutics is $341.59 million. Monte Rosa Therapeutics has a price to earnings ratio (PE ratio) of -2.52.

      Ask ADVFN Intelligence (AI)

      GLUE Latest News

      More News

      Form 8-K - Current report

      January 10 2025
      Edgar (US Regulatory)

      Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

      Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Additional clinical results from Phase 1/2 study of MRT-2359 in...

      January 10 2025
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      January 06 2025
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      January 06 2025
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      January 06 2025
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      January 06 2025
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      January 06 2025
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      January 06 2025
      Edgar (US Regulatory)

      Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines...

      January 06 2025
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      December 13 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.86-13.39563862936.426.4755.3810146835.72251534CS
      4-2.11-27.50977835727.677.895.3811813536.63948364CS
      120.35.703422053235.2612.44.7630431538.97930861CS
      261.1626.36363636364.412.43.5215454518.53685228CS
      52-0.44-7.33333333333612.43.328753968.195965CS
      156-8.93-61.628709454814.4915.8252.444345908.13263591CS
      260-16.44-74.72727272732245.562.444001659.54483837CS

      GLUE - Frequently Asked Questions (FAQ)

      What is the current Monte Rosa Therapeutics share price?
      The current share price of Monte Rosa Therapeutics is $ 5.56
      How many Monte Rosa Therapeutics shares are in issue?
      Monte Rosa Therapeutics has 61,436,740 shares in issue
      What is the market cap of Monte Rosa Therapeutics?
      The market capitalisation of Monte Rosa Therapeutics is USD 341.59M
      What is the 1 year trading range for Monte Rosa Therapeutics share price?
      Monte Rosa Therapeutics has traded in the range of $ 3.32 to $ 12.40 during the past year
      What is the PE ratio of Monte Rosa Therapeutics?
      The price to earnings ratio of Monte Rosa Therapeutics is -2.52
      What is the reporting currency for Monte Rosa Therapeutics?
      Monte Rosa Therapeutics reports financial results in USD
      What is the latest annual profit for Monte Rosa Therapeutics?
      The latest annual profit of Monte Rosa Therapeutics is USD -135.35M
      What is the registered address of Monte Rosa Therapeutics?
      The registered address for Monte Rosa Therapeutics is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
      What is the Monte Rosa Therapeutics website address?
      The website address for Monte Rosa Therapeutics is www.monterosatx.com.
      Which industry sector does Monte Rosa Therapeutics operate in?
      Monte Rosa Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AALAmerican Airlines Group Inc
      $ 18.21
      (0.00%)
      		0
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 71.1249
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 2.995
      (0.00%)
      		0
      AACGATA Creativity Global
      $ 0.91995
      (0.00%)
      		0
      AALAmerican Airlines Group Inc
      $ 18.21
      (0.00%)
      		0
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 71.1249
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 2.995
      (0.00%)
      		0
      AACGATA Creativity Global
      $ 0.91995
      (0.00%)
      		0
      AALAmerican Airlines Group Inc
      $ 18.21
      (0.00%)
      		0
      AAGRAfrican Agriculture Holdings Inc
      $ 0.1326
      (0.00%)
      		0
      AADRAdvisorShares Dorsey Wright ADR ETF
      $ 71.1249
      (0.00%)
      		0
      AADIAadi Bioscience Inc
      $ 2.995
      (0.00%)
      		0
      AACGATA Creativity Global
      $ 0.91995
      (0.00%)
      		0

      GLUE Discussion

      View Posts
      Monksdream Monksdream 3 weeks ago
      GLUE, under $7

      👍️0
      corncakes0 corncakes0 2 months ago
      Hmm
      👍️0
      Woodpecker3 Woodpecker3 3 months ago
      $GLUE investors have been in what Cramer calls "the house of pain" for months. Many purchased this at $40,$50,$60,$70 per share. The company will be added to the long list of biotech failures once the inevitable FDA trial failure is confirmed.
      👍️0
      Woodpecker3 Woodpecker3 3 months ago
      $GLUE will soon be added to this list

      https://www.fiercebiotech.com/special-reports/2023s-top-10-clinical-trial-flops

      👍️0
      Woodpecker3 Woodpecker3 3 months ago
      $GLUE trapped alot of "investors" earlier this week at 10+ all the way to 12.50/Share. It is cratering just as precipitously. Watch for less than 8....7.....6... in days to come.
      👍️0
      Woodpecker3 Woodpecker3 3 months ago
      $GLUE - No products. no revenues, massive losses, running out of cash. Millions of shares avaiable to short. Looking for $5/share
      👍️0
      Monksdream Monksdream 4 months ago
      GLUE under $7
      👍️0
      Monksdream Monksdream 4 months ago
      GLUE under $6
      👍️0
      Monksdream Monksdream 6 months ago
      GLUE under $5
      👍️0
      Monksdream Monksdream 6 months ago
      GLUE under $5
      👍️0

      Your Recent History

      NASDAQ
      GLUE
      Monte Rosa Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads